Naloxone Polpharma (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxone Polpharma, is an opioid antagonist presented as an injection solution for intramuscular, intravenous, or subcutaneous administration. It rapidly reverses the life‑threatening effects of opioid overdose in both adults and children.

GNH USA supplies Naloxone Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets. Manufactured in the European Union, the product meets EU pharmacopoeial standards. and is available for immediate distribution.

Naloxone Polpharma, an opioid antagonist, is used to counteract opioid toxicity.

Heroin overdose: restores breathing and consciousness in patients experiencing heroin‑induced respiratory depression. Prescription opioid overdose: reverses life‑threatening effects of medications such as morphine, oxycodone, or hydromorphone. Fentanyl or synthetic opioid overdose: rapidly counteracts potent opioid toxicity when standard doses are insufficient.

Naloxone Polpharma may cause a range of adverse reactions following administration.

Common Side Effects: - Nausea - Vomiting - Sweating - Tachycardia - Hypertension - Agitation - Headache

Serious or Rare Side Effects: - Severe hypertension - Cardiac arrhythmia - Pulmonary edema - Seizures - Anaphylactic reaction - Acute opioid withdrawal syndrome

When using Naloxone Polpharma, several safety considerations should be observed.

Assess airway and breathing: ensure the patient can maintain a patent airway before administration. Monitor vital signs: observe blood pressure, heart rate, and respiratory status after dosing. Consider opioid dependence: patients may experience acute withdrawal symptoms. Avoid use in patients with known hypersensitivity to naloxone. Pregnancy and lactation: use only if the benefit outweighs the potential risk; data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone Polpharma can interact with other substances that affect the central nervous system or cardiovascular response.

Major Interactions (Avoid): - Opioid agonists with high affinity (e.g., buprenorphine): may reduce naloxone effectiveness. - Monoamine oxidase inhibitors: may potentiate hypertensive response. - Beta‑blockers: may mask tachycardia, complicating assessment.

Moderate Interactions (Monitor Closely): - Benzodiazepines: may require additional respiratory support. - Alcohol: additive CNS depression; monitor respiratory function. - Tricyclic antidepressants: increased risk of seizures; observe closely.